

# BIOLIN MEDICAL

## Press Release

Stockholm, July 6, 2000

### BIOLIN MEDICAL STRENGTHENS MANAGEMENT

Stefan Hansson joins Biolin Medical as Head of investment operations. He will also be a member of Corporate Management. Mr. Hansson comes most recently from ABG Securities where he worked as an analyst. In total he has 14 years of experience from the equity markets, mostly within research and corporate finance.

"We are very happy that Stefan has decided to join us. Biolin is set to expand the capital base as well as the number of investments in the portfolio. In this phase he brings a lot of value to Biolin and our shareholders, given his broad experience from the capital markets," says Per Spångberg, CEO of Biolin Medical AB.

For further information:

Per Spångberg, CEO, +46-8-679 90 10 or +46-70-485 26 39

Claes Holmberg, Board member, +46-31-336 91 01 or +46-70-825 45 47

*Biolin Medical is a venture-capital company that creates value growth in high-technology companies in biotechnology, medical technology and related areas. Through an operative owner commitment based on unique competence and a comprehensive network, Biolin develops innovations for commercial companies. Biolin's investment portfolio consists of ownership in the companies BST Blood Saving Technologies, Boule Diagnostics, Cavidit Tech, Integration Diagnostics, Q-Sense and Sinterkil.*